StaphVAX Immunogenicity and Safety in Orthopaedic Joint Surgery

PHASE3CompletedINTERVENTIONAL
Enrollment

67

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

May 31, 2006

Study Completion Date

August 31, 2006

Conditions
Staphylococcal Infections
Interventions
BIOLOGICAL

S. aureus Types 5 and 8 Capsular Polysaccharide Conjugate

single IM dose of 200 mcg total conjugate

BIOLOGICAL

placebo

single dose IM

Trial Locations (1)

HA7 4LP

National Royal Orthopaedic Hospital, Stanmore

Sponsors
All Listed Sponsors
collaborator

Public Health England

OTHER_GOV

lead

Nabi Biopharmaceuticals

INDUSTRY

NCT00211965 - StaphVAX Immunogenicity and Safety in Orthopaedic Joint Surgery | Biotech Hunter | Biotech Hunter